20 June 2018

Fortress Biotech, formerly Coronado Biosciences Inc, announces publication in the journal Biology of Blood and Marrow Transplantation of positive Phase 1 clinical trial data evaluating technology licensed from UCLB, in the form of CNDO-109-activated allogeneic natural killer (NK) cells, in patients with acute myeloid leukemia (AML).

Learn more here: